Last reviewed · How we verify

PREDNISOLONE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 21/100

PREDNISOLONE is a drug. It is currently FDA-approved (first approved 1955).

Prednisolone is a small molecule that acts as a glucocorticoid receptor agonist. It has been studied in clinical trials for various conditions, including cervical radiculopathy, carpal tunnel syndrome, and lung cancer, among others.

At a glance

Generic namePREDNISOLONE
ModalitySmall molecule
PhaseFDA-approved
First approval1955

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PREDNISOLONE

What is PREDNISOLONE?

PREDNISOLONE is a Small molecule drug.

When was PREDNISOLONE approved?

PREDNISOLONE was first approved on 1955.

What development phase is PREDNISOLONE in?

PREDNISOLONE is FDA-approved (marketed).

What are the side effects of PREDNISOLONE?

Common side effects of PREDNISOLONE include Congestive heart failure, Osteoporosis, Vertebral compression fractures, Aseptic necrosis of femoral and humeral heads, Pathologic fracture of long bones, Peptic ulcer with possible perforation and hemorrhage.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing